You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

396 Results
Drug
Other Name(s): Trodelvy®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jul 2025
Drug
Other Name(s): Enhertu®
Quick Link(s): Drug Monograph, Patient Info Sheet
May 2025
Regimen
Cancer Type:
Endocrine, 
Thyroid
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    selpercatinib - For the treatments of advanced or metastatic RET fusion-positive differentiated thyroid carcinoma (DTC); and unresectable advanced or metastatic RET-mutant medullary thyroid cancer (MTC)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
selpercatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2025
Guidelines and Advice
Status: Current
ID: PET 2023-1
Nov 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Epcoritamab (Outpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma
High Cost Therapy Funding Program
    Epcoritamab (Inpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
epcoritamab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2025
Drug
Other Name(s): Xpovio®
Quick Link(s): Drug Monograph, Patient Info Sheet
Mar 2024
The following information answers many of the questions primary care physicians commonly ask about the Screening Activity Report and the included...
Guidelines and Advice
Status: Current
Version: PET 2023-2
Jun 2024
Symptom Management

Pages